BRIEF published on 11/19/2025 at 13:52, 6 months 4 days ago Calendrier financier 2026 de Guerbet Calendrier Financier Résultats Annuels Assemblée Générale Guerbet Imagerie Médicale
PRESS RELEASE published on 11/19/2025 at 13:47, 6 months 4 days ago GUERBET : Financial agenda for 2026 Guerbet announces financial agenda for 2026 with key dates for publications and meetings in the medical imaging sector Financial Agenda Guerbet Medical Imaging Publications 2026
PRESS RELEASE published on 11/19/2025 at 13:47, 6 months 4 days ago GUERBET : Calendrier financier de l’exercice 2026 Guerbet (FR0000032526 GBT) publie son calendrier financier 2026 avec dates des publications des chiffres d'affaires et des résultats annuels et trimestriels Chiffre D'affaires Calendrier Financier Résultats Annuels Guerbet Exercice 2026
BRIEF published on 09/25/2025 at 09:26, 7 months 28 days ago GUERBET : Publication du Rapport Financier Semestriel 2025 Rapport Financier Guerbet Imagerie Médicale 2025 Produits De Contraste
BRIEF published on 09/25/2025 at 09:26, 7 months 28 days ago GUERBET: Publication of the 2025 Half-Yearly Financial Report Financial Report Guerbet Medical Imaging 2025 Contrast Agents
PRESS RELEASE published on 09/25/2025 at 09:21, 7 months 28 days ago GUERBET : Mise à disposition du rapport financier semestriel 2025 Guerbet annonce la mise à disposition de son Rapport Financier semestriel 2025 auprès du public et de l'AMF. Consultation sur www.guerbet.com. Prochain RDV : publication chiffre d’affaires 3ème trimestre 2025 Chiffre D’affaires AMF Rapport Financier Guerbet Semestriel
PRESS RELEASE published on 09/25/2025 at 09:08, 7 months 28 days ago Rapport financier semestriel 2025
BRIEF published on 09/22/2025 at 17:50, 8 months 1 day ago Guerbet Announces Interim CEO Amid Leadership Change Interim CEO Guerbet Medical Imaging Leadership Change Jerome Estampes
BRIEF published on 09/22/2025 at 17:50, 8 months 1 day ago Guerbet annonce la nomination d'un PDG par intérim dans le cadre d'un changement de direction Changement De Direction Guerbet Imagerie Médicale PDG Par Intérim Jerome Estampes
PRESS RELEASE published on 09/22/2025 at 17:45, 8 months 1 day ago Guerbet : Change in General Management Guerbet appoints Jérôme Estampes as interim CEO, replacing David Hale. Smooth transition expected with Executive Committee support. Nominations process underway for new CEO CEO Appointment Guerbet Transition Jerome Estampes Nominations Process
Published on 05/23/2026 at 19:45, 9 hours 58 minutes ago Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day 2 hours ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day 2 hours ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 3 hours ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 3 hours ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/24/2026 at 05:35, 7 minutes ago CGTN: Xizang at 75: Development and culture create a 'miracle on Earth'
Published on 05/23/2026 at 16:30, 13 hours 12 minutes ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 13 hours 46 minutes ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 7 hours ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 1 day 7 hours ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:35, 1 day 10 hours ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 11 hours ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 11 hours ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 16 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 16 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
